Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01542918 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
A Phase 1 study, sponsored by James Rubenstein.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01542918 is a Phase 1 study that has completed, run by James Rubenstein. The registered enrollment target is 14 participants.
The verdict
NCT01542918, a Phase 1 study, has completed, sponsored by James Rubenstein.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase I study, which means that the goal is to see if the study treatment is safe. The purpose of this study is to test the safety of Lenalidomide at different dose levels, and to test the safety of Lenalidomide alone or in combination with Rituximab (also known as Rituxan®).
Interventions
- DRUG Rituximab
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-12-17 |
| Est. Completion | 2016-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01542918
The ClinicalTrials.gov registry entry for NCT01542918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Rubenstein, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01542918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01542918 about?
NCT01542918 is a clinical study titled "Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma". This is a Phase I study, which means that the goal is to see if the study treatment is safe. The purpose of this study is to test the safety of Lenalidomide at different dose levels, and to test the safety of Lenalidomide alone or in combination with Rituximab (also known as Rituxan®).
What is the current status of trial NCT01542918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-12-17. Estimated completion is 2016-08-30.
What interventions are being tested in trial NCT01542918?
The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01542918?
This trial is sponsored by James Rubenstein, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.